Based on the results of that study, we recruited 30 patients with breast cancer for a clinical trial to further evaluate the potential application of 99mTc-NM-02 as a single photon emission computed tomography (SPECT) probe for HER2 expression assessment. This evidence concerns the gene ERBB2 and breast carcinoma.